ATYRNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
aTYR PHARMA INC
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026
$0.17−0.00 (-1.32%)
Close on Oct 19, 2026
- Market cap
- $16.84M
- P/E (TTM)
- –
- Dividend yield
- –
aTYR PHARMA statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Biological Products, (No Diagnostic Substances) companies for comparison
Valuation
| Measure | aTYR PHARMA | Industry median |
|---|---|---|
| Market Cap | $16.84M | $197.05M |
| Enterprise Value | -$40.77M | $106.56M |
| PB Ratio | 0.35 | 2.14 |
| P/TBV Ratio | 0.35 | 2.46 |
Income (trailing twelve months)
| Measure | aTYR PHARMA | Industry median |
|---|---|---|
| Operating Income | -$63.86M | -$21.44M |
| Net Income | -$60.81M | -$22.46M |
| EBITDA | -$63.20M | -$16.91M |
| EPS (Diluted) | -$0.62 | -$0.83 |
Returns
| Measure | aTYR PHARMA | Industry median |
|---|---|---|
| Return on Equity (ROE) | -98.4% | -53.1% |
| Return on Assets (ROA) | -71.0% | -41.0% |
| Return on Capital Employed (ROCE) | -109.3% | -37.8% |
Growth
| Measure | aTYR PHARMA | Industry median |
|---|---|---|
| Revenue Growth (3Y CAGR) | -73.7% | 2.25% |
| Revenue Growth (5Y CAGR) | -55.1% | 6.42% |
Balance sheet
| Measure | aTYR PHARMA | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $57.42M | $62.42M |
| Net Cash (Debt) | $57.42M | $15.68M |
| Net Cash Per Share | $0.59 | $0.65 |
| Equity (Book Value) | $48.79M | $48.79M |
| Book Value Per Share | $0.50 | $1.36 |
| Tangible Book Value | $48.79M | $23.06M |
| Working Capital | $46.97M | $75.77M |
Financial position
| Measure | aTYR PHARMA | Industry median |
|---|---|---|
| Current Ratio | 5.12 | 3.30 |
| Quick Ratio | 5.04 | 2.39 |
Cash flow (trailing twelve months)
| Measure | aTYR PHARMA | Industry median |
|---|---|---|
| Operating Cash Flow | -$54.54M | -$12.35M |
| Capital Expenditures | -$279.00K | -$1.06M |
| Free Cash Flow | -$54.82M | -$20.28M |
| FCF Per Share | -$0.56 | -$0.41 |
Efficiency
| Measure | aTYR PHARMA | Industry median |
|---|---|---|
| Profits Per Employee | -$1.05M | -$732.08K |
| Employee Count | 58 | 73 |
Dividends and yields
| Measure | aTYR PHARMA | Industry median |
|---|---|---|
| Earnings Yield | -361.1% | -21.2% |
| FCF Yield | -325.5% | -7.64% |
Shares
| Measure | aTYR PHARMA | Industry median |
|---|---|---|
| Shares Outstanding | 98,087,400 | 59,128,900 |
| Shares Change (YoY) | 16.7% | 11.1% |
| Shares Change (QoQ) | 0.04% | 0.54% |
| Float | 95,584,600 | 48,744,500 |
| Shares Held by Insiders | 2.55% | 11.8% |
| Shares Held by Institutions | 41.4% | 59.4% |
Scores
| Measure | aTYR PHARMA | Industry median |
|---|---|---|
| Altman Z-Score | -14.31 | 0.10 |
| Piotroski F-Score | 3 | 4 |
Calculated by StockData from aTYR PHARMA's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.